Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial - Urasinski, T.; Stasyshyn, O.; Andreeva, T.; Rusen, L.; Perina, F. G.; Oh, M. S.; Chapman, M.; Pavlova, B. G.; Valenta-Singer, B.; Abbuehl, B. E. (Haemophilia : the official journal of the World Federation of Hemophilia, 2015)
Keywords: Adolescent; Age Factors; Child; Child, Preschool; Clinical trials; Coagulation factors; Factor IX - pharmacology; Factor IX - therapeutic use; Factor IX deficiency; Female; haemophilia B; Hemophilia; Hemophilia B - blood; Hemophilia B - complications; Hemophilia B - drug therapy; Hemorrhage - drug therapy; Hemorrhage - etiology; Hemorrhage - prevention & control; Humans; Infant; Male; paediatric; Patients; Pediatrics; Pharmacokinetics; Premedication; previously treated patients; Prophylaxis; recombinant factor IX; Recombinant Proteins - pharmacology; Recombinant Proteins - therapeutic use; Retreatment; Time Factors; Treatment Outcome; previously treated patients; haemophilia B; recombinant factor IX; paediatric